Lysophosphatidic acid induces prostate cancer PC3 cell migration via activation of LPA1, p42 and p38α

被引:75
作者
Hao, Feng
Tan, Mingqi
Xu, Xuemin
Han, Jiahuai
Miller, Duane D.
Tigyi, Gabor
Cui, Mei-Zhen
机构
[1] Univ Tennessee, Coll Vet Med, Dept Pathobiol, Knoxville, TN 37996 USA
[2] Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA
[3] Univ Tennessee, Ctr Hlth Sci, Dept Pharmaceut Sci, Memphis, TN 38163 USA
[4] Univ Tennessee, Ctr Hlth Sci, Dept Physiol, Memphis, TN 38163 USA
来源
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS | 2007年 / 1771卷 / 07期
关键词
lysophosphatidic acid; receptors; cell migration; protein kinases and prostate cancer cells; PROTEIN-COUPLED RECEPTOR; KINASE KINASE; P38; GROUP; EXPRESSION; GROWTH; PATHWAY; LYSOPHOSPHOLIPIDS; AUTOPSY; MEMBER; GPR92;
D O I
10.1016/j.bbalip.2007.04.010
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Prostate cancer cell migration is an essential event both in the progression of prostate cancer and in the steps leading to metastasis. We report here that lysophosphatidic acid (LPA), a potent bioactive phospholipid, induces prostate cancer PC3 cell migration via the activati on of the LPA, receptor, which is linked to a PTX-seiisitive activation mechanism of the mitogen-activated protein kinases (MAPK). Our results demonstrate that parallel activation of ERK1/2 and p38, but not JNK, is responsible for LPA-stiniulated PC3 cell migration. Furthermore, using small interfering RNA (siRNA) technology, and overexpressing dominant-negative mutants of p38 MAPK isotypes of alpha, beta, gamma and delta, we have identified that the activation of ERK2 (p42) and p38 alpha, but not of ERK1 and the other isoforms of p38 MAPK, is required for LPA-induced migration. Our study provides the first evidence for a functional role of p42 and p38 alpha in LPA-induced mammalian cell migration, and also demonstrates, for the first time, that the receptor LPA(1) mediates prostate cancer cell migration. The results of the present study suggest that LPA the receptor LPA(1), ERK2 and p38 alpha are important regulators for prostate cancer cell invasion and thus could play a significant role in the development of metastasis.(c) 2007 Elsevier B.V. All rights reserved.
引用
收藏
页码:883 / 892
页数:10
相关论文
共 42 条
[21]   GPR92 as a new G12/13- and Gq-coupled lysophosphatidic acid receptor that increases cAMP, LPA5 [J].
Lee, Chang-Wook ;
Rivera, Richard ;
Gardell, Shannon ;
Dubin, Adrienne E. ;
Chun, Jerold .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2006, 281 (33) :23589-23597
[22]   The primary structure of p38 gamma: A new member of p38 group of MAP kinases [J].
Li, ZJ ;
Jiang, Y ;
Ulevitch, RJ ;
Han, JH .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1996, 228 (02) :334-340
[23]   Pathogenesis and treatment of prostate cancer bone metastases: Targeting the lethal phenotype [J].
Loberg, RD ;
Logothetis, CJ ;
Keller, ET ;
Pienta, KJ .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (32) :8232-8241
[24]   The emerging role of lysophosphatidic acid in cancer [J].
Mills, GB ;
Moolenaar, WH .
NATURE REVIEWS CANCER, 2003, 3 (08) :582-591
[25]   Bioactive lysophospholipids and their G protein-coupled receptors [J].
Moolenaar, WH .
EXPERIMENTAL CELL RESEARCH, 1999, 253 (01) :230-238
[26]   Of spiders and crabs: The emergence of lysophospholipids and their metabolic pathways as targets for therapy in cancer [J].
Murph, Mandi ;
Tanaka, Tamotsu ;
Liu, Shuying ;
Mills, Gordon B. .
CLINICAL CANCER RESEARCH, 2006, 12 (22) :6598-6602
[27]   Identification of p2y9/GPR23 as a novel G protein-coupled receptor for lysophosphatidic acid, structurally distant from the Edg family [J].
Noguchi, K ;
Ishii, S ;
Shimizu, T .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (28) :25600-25606
[28]   The p38 signal transduction pathway - Activation and function [J].
Ono, K ;
Han, JH .
CELLULAR SIGNALLING, 2000, 12 (01) :1-13
[29]   Activation of extracellular signal-regulated kinase in human prostate cancer [J].
Price, DT ;
Della Rocca, G ;
Guo, CH ;
Ballo, MS ;
Schwinn, DA ;
Luttrell, LM .
JOURNAL OF UROLOGY, 1999, 162 (04) :1537-1542
[30]  
Putz T, 1999, CANCER RES, V59, P227